Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2017

  • ID: 4418953
  • Report
  • 93 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Amgen Inc
  • Cold Genesys Inc
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • Mologen AG
  • MORE
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2017

Summary

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2017, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 3 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Breast Cancer, Rheumatoid Arthritis, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Prostate Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Colorectal Cancer, Glioblastoma Multiforme (GBM), Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis Pain, Ovarian Cancer, Pancreatic Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma and Squamous Cell Carcinoma.

Furthermore, this report also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Amgen Inc
  • Cold Genesys Inc
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • Mologen AG
  • MORE
Introduction

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development

Aduro BioTech Inc

Amgen Inc

BriaCell Therapeutics Corp

Cold Genesys Inc

GlaxoSmithKline Plc

Humanigen Inc

Mologen AG

Morphotek Inc

Sillajen Biotherapeutics

Takeda Pharmaceutical Co Ltd

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles

Cellular Immunotherapy to Activate GMCSF for Breast Cancer - Drug Profile

CG-0070 - Drug Profile

CG-0070 + Immune Checkpoint Modulator - Drug Profile

gimsilumab - Drug Profile

GSK-3196165 - Drug Profile

lenzilumab - Drug Profile

MGN-1601 - Drug Profile

Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile

namilumab - Drug Profile

OrienX-010 - Drug Profile

pexastimogene devacirepvec - Drug Profile

SBPL-0100 - Drug Profile

STINGVAX - Drug Profile

SVBR-1GM - Drug Profile

talimogene laherparepvec - Drug Profile

Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Aduro BioTech Inc, H2

Pipeline by Amgen Inc, H2

Pipeline by BriaCell Therapeutics Corp, H2

Pipeline by Cold Genesys Inc, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Humanigen Inc, H2

Pipeline by Mologen AG, H2

Pipeline by Morphotek Inc, H2

Pipeline by Sillajen Biotherapeutics, H2

Pipeline by Takeda Pharmaceutical Co Ltd, H2

Dormant Products, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aduro BioTech Inc
  • Amgen Inc
  • BriaCell Therapeutics Corp
  • Cold Genesys Inc
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • Mologen AG
  • Morphotek Inc
  • Sillajen Biotherapeutics
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll